Cas 134790-39-9 Synthesis Route & Manufacturing Process
Securing a stable supply of Gemcitabine Intermediate 9 requires navigating complex synthesis route variables that impact industrial purity and downstream yield.
At NINGBO INNO PHARMCHEM CO.,LTD., we understand the critical nature of nucleoside analogs in oncology drug development. Our optimized manufacturing process for 2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate ensures consistent quality for global manufacturers seeking reliable pharmaceutical grade materials.
Technical Specifications and Analytical Methods
| Parameter | Specification |
|---|---|
| CAS Number | 134790-39-9 |
| Molecular Formula | C23H19F2N3O6 |
| Molecular Weight | 471.41 g/mol |
| Purity (HPLC) | >98.5% |
| Beta-Isomer Content | <0.1% |
| Analysis Method | HPLC, NMR, MS |
Troubleshooting Common Impurities and Yield Issues
Controlling Beta-Isomer Content
Maintaining low beta-isomer levels is crucial for downstream coupling efficiency. Historical data suggests optimized reflux conditions can reduce isomer content to below 0.08%. For detailed verification protocols, review our insights on Dfdct-Dibenzoate Pharmaceutical Grade Coa Industrial Purity to ensure batch consistency.
Optimizing Benzoylation Yield
Achieving yields above 85% requires precise temperature control during the heating phase, typically around 120°C for 3 hours. Procurement teams should evaluate long-term cost implications by analyzing Gemcitabine Intermediate 9 Bulk Price 2026 trends to secure favorable contracts.
Strict Quality Assurance Workflow and COA Verification
Every batch undergoes rigorous testing to meet GMP standards. Our COA verification process includes multi-point identity checks and impurity profiling. NINGBO INNO PHARMCHEM CO.,LTD. guarantees that all documentation aligns with regulatory requirements for industrial purity and safety.
For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.